News Sentiment

CURX sentiment intelligence

Curanex Pharmaceuticals Inc Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.21 Week of 17 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

-7.7% over one week, -26.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Curanex Pharmaceuticals (CURX) Edges Higher on Modest Gains, Testing Key Resistance at $0.23 - Cup and Handle

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -7.7% Price reacting lower
Trend fit Trend inactive -26.5% over four weeks
Fair value -76.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 30
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingView 8
TradingKey 8
Stock Titan 7
dars.gov.et 3
Investing.com Nigeria 2
simplywall.st 2
Barron's 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 19
Regulatory and legal 3
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-52 of 52
Stock Titan Direct company coverage

Curanex (Nasdaq: CURX) advances Phyto-N toward Q4 2026 IND and adds cancer cachexia

Curanex (CURX) provided a Q1 2026 business update, detailing progress for its lead drug candidate, Phyto-N, towards a Q4 2026 Investigational New Drug (IND) submission for ulcerative colitis. The company completed GMP manufacturing and a 28-day toxicology study with favorable res

Tone
Positive 64/100
Event
Regulatory and legal
Published
14 May 2026 13:15
Source
Stock Titan
Investing.com Canada Direct company coverage

Curanex completes manufacturing, toxicology work for ulcerative colitis drug By Investing.com

Curanex Pharmaceuticals Inc. (NASDAQ:CURX) has completed manufacturing a GMP-compliant batch of Phyto-N and finished toxicology studies for its ulcerative colitis drug candidate. The company plans to submit an Investigational New Drug application to the FDA in Q4 2026 and is also

Tone
Positive 73/100
Event
Regulatory and legal
Published
14 May 2026 13:08
Source
Investing.com Canada
Stock Titan Direct company coverage

Curanex (NASDAQ: CURX) ramps Phyto-N R&D as Nasdaq listing faces bid-price deadline

Curanex Pharmaceuticals (CURX) reported a net loss of $3.15 million in Q1 2026, widening from the previous year, primarily due to increased R&D spending on its botanical drug pipeline, Phyto-N. The company has made progress in manufacturing and toxicology studies for Phyto-N, and

Tone
Negative 35/100
Event
Market update
Published
14 May 2026 13:08
Source
Stock Titan
TradingView Direct company coverage

Curanex Pharmaceuticals Inc 1Q 2026: Net income $(3.15M), EPS $(0.11) — 10-Q Summary

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $(3.15M) for Q1 2026, widening from $(137.6K) in Q1 2025, with diluted EPS at $(0.11) against $(0.01) in the prior year. The company completed a GMP pilot-scale batch of Phyto-N and aims for an IND submission in Q4 2026 fo

Tone
Negative 20/100
Event
Earnings
Published
14 May 2026 13:08
Source
TradingView
TradingKey Direct company coverage

Curanex Pharmaceuticals Inc (CURX) Stock Price

This page provides real-time stock information for Curanex Pharmaceuticals Inc (CURX), showing its current trading price, daily change, and market capitalization. It also offers quick links to financial data, discussions, and analysis for the company, and notes that its quotes ar

Tone
Neutral 50/100
Event
Market update
Published
12 May 2026 15:10
Source
TradingKey
Investing.com Nigeria Direct company coverage

Curanex Pharmaceuticals receives extension from Nasdaq to regain bid price compliance

Curanex Pharmaceuticals (NASDAQ: CURX) has been granted an additional 180-day extension by Nasdaq to meet the minimum $1.00 bid price requirement for continued listing. The company's stock currently trades at $0.33, down significantly over the past year. Curanex will monitor its

Tone
Negative 36/100
Event
Market update
Published
08 May 2026 17:10
Source
Investing.com Nigeria